UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 464

Sortiert nach

In Vivo Silencing of the Transcription Factor IRF5 Reprograms the Macrophage Phenotype and Improves Infarct Healing

Journal of the American College of Cardiology, 2014-04, Vol.63 (15), p.1556-1566

2014

Volltextzugriff (PDF)

Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis

Blood, 2017-08, Vol.130 (9), p.1132-1143

2017

Volltextzugriff (PDF)

Antibodies Targeting Human or Mouse VSIG4 Repolarize Tumor-Associated Macrophages Providing the Potential of Potent and Specific Clinical Anti-Tumor Response Induced across Multiple Cancer Types

International journal of molecular sciences, 2024-06, Vol.25 (11), p.6160

2024

Volltextzugriff (PDF)

Influence of Cationic Lipid Composition on Gene Silencing Properties of Lipid Nanoparticle Formulations of siRNA in Antigen-Presenting Cells

Molecular therapy, 2011-12, Vol.19 (12), p.2186-2200

2011

Volltextzugriff (PDF)

Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy

Molecular cancer therapeutics, 2017-03, Vol.16 (3), p.428-439

2017

Volltextzugriff (PDF)

Power Mechanisms of Rotational and Cyclic Motions

1, 2015

Volltextzugriff (PDF)

The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors

Molecular cancer therapeutics, 2017-03, Vol.16 (3), p.417-427

2017

Volltextzugriff (PDF)

Rates of return of investments whose timings are specified by a probability distribution

The Engineering economist, 2020-10, Vol.65 (4), p.363-380

Klebanov, Boris

2020

Volltextzugriff (PDF)

Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells

Molecular therapy. Nucleic acids, 2012-01, Vol.1 (1), p.e4-e4, Article e4

2012

Volltextzugriff (PDF)

886 Targeting VSIG4, a novel macrophage checkpoint, repolarizes suppressive macrophages which induces an inflammatory response in primary cell in vitro assays and fresh human tumor cultures

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A928-A928

2021

Volltextzugriff (PDF)

Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity

Nature communications, 2014-06, Vol.5 (1), p.4277-4277, Article 4277

2014

Volltextzugriff (PDF)

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia

Blood, 2017-06, Vol.129 (24), p.3165-3174

2017

Volltextzugriff (PDF)

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death

Oncotarget, 2016-11, Vol.7 (48), p.78883-78895

2016

Volltextzugriff (PDF)

Abstract P105: Targeting VSIG4, a novel macrophage checkpoint, repolarizes suppressive macrophages which induces an inflammatory response in primary cell in vitro assays and fresh human tumor cultures

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P105-P105

2021

Volltextzugriff (PDF)

Cutting Edge: Hypoxia-Inducible Factor 1α and Its Activation-Inducible Short Isoform I.1 Negatively Regulate Functions of CD4+ and CD8+ T Lymphocytes

The Journal of immunology (1950), 2006-10, Vol.177 (8), p.4962-4965

2006

Volltextzugriff (PDF)

The principles of multi-agent models of development based on the needs of the agents

2016 35th Chinese Control Conference (CCC), 2016, p.7551-7555

2016

Volltextzugriff (PDF)

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) Compound, Shows Synergistic Anti-Tumor Activity in Combination with Dexamethasone Characterized By Specific Pattern of Gene Expression in Multiple Myeloma (MM)

Blood, 2015-12, Vol.126 (23), p.3683-3683

2015

Volltextzugriff (PDF)

Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death

Oncotarget, 2018-05, Vol.9 (39), p.25529-25544

2018

Volltextzugriff (PDF)

Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents

Oncotarget, 2018-07, Vol.9 (56), p.30773-30786

2018

Volltextzugriff (PDF)

Abstract 4146: Selinexor synergizes with DNA damaging agents through down-regulation of key DNA damage response genes

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4146-4146

2017

Volltextzugriff (PDF)

Abstract 1587: Disruption of nuclear export with selinexor or KPT-8602 reduces androgen receptor expression and leads to potent anti-tumor activity in preclinical models of androgen-independent prostate cancer

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1587-1587

2017

Volltextzugriff (PDF)

Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds

BMC cancer, 2015-11, Vol.15 (909), p.910, Article 910

2015

Volltextzugriff (PDF)

Efficacy of Selinexor Is Dependent on IκB-α Expression and NF-Kb Deactivation in Multiple Myeloma Cells

Blood, 2016-12, Vol.128 (22), p.5660-5660

2016

Volltextzugriff (PDF)

Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T Cell Effector Function in Mice: Implications for Combination with Immunotherapy

Blood, 2016-12, Vol.128 (22), p.2525-2525

2016

Volltextzugriff (PDF)

1 – 25 von 464

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(462)

Publikationsform

Sprache

Englisch
(464)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(59)
Aerospace & Radar Technology
(44)
General References
(44)
Technology
(40)
Engineering
(36)
Engineering, Mechanical
(35)
Life Sciences & Biomedicine
(15)
Animals
(10)
Automotive Technology
(7)
Environmental Engineering & Technology
(7)
Humans
(7)
Mice
(7)
Technical Design
(7)
Oncology
(6)
Physical Sciences
(6)
Cancer
(4)
Cell Line, Tumor
(4)
Exportin 1 Protein
(4)
Female
(4)
Lymphocytes
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

In Vivo Silencing of the Transcription Factor IRF5 Reprograms the Macrophage Phenotype and Improves Infarct Healing

Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis

Antibodies Targeting Human or Mouse VSIG4 Repolarize Tumor-Associated Macrophages Providing the Potential of Potent and Specific Clinical Anti-Tumor Response Induced across Multiple Cancer Types

Influence of Cationic Lipid Composition on Gene Silencing Properties of Lipid Nanoparticle Formulations of siRNA in Antigen-Presenting Cells

Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy

Power Mechanisms of Rotational and Cyclic Motions

The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors

Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody

Rates of return of investments whose timings are specified by a probability distribution

Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells

886 Targeting VSIG4, a novel macrophage checkpoint, repolarizes suppressive macrophages which induces an inflammatory response in primary cell in vitro assays and fresh human tumor cultures

Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death

Abstract P105: Targeting VSIG4, a novel macrophage checkpoint, repolarizes suppressive macrophages which induces an inflammatory response in primary cell in vitro assays and fresh human tumor cultures

Cutting Edge: Hypoxia-Inducible Factor 1α and Its Activation-Inducible Short Isoform I.1 Negatively Regulate Functions of CD4+ and CD8+ T Lymphocytes

The principles of multi-agent models of development based on the needs of the agents

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) Compound, Shows Synergistic Anti-Tumor Activity in Combination with Dexamethasone Characterized By Specific Pattern of Gene Expression in Multiple Myeloma (MM)

Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death

Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents

Abstract 4146: Selinexor synergizes with DNA damaging agents through down-regulation of key DNA damage response genes

Abstract 1587: Disruption of nuclear export with selinexor or KPT-8602 reduces androgen receptor expression and leads to potent anti-tumor activity in preclinical models of androgen-independent prostate cancer

Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds

Efficacy of Selinexor Is Dependent on IκB-α Expression and NF-Kb Deactivation in Multiple Myeloma Cells

Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T Cell Effector Function in Mice: Implications for Combination with Immunotherapy

Suchergebnisse filtern